Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC

NCT03990077 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped drug development strategy adjustment

Conditions

Nsclc

Interventions

DRUG: HL-085
DRUG: Docetaxel

Sponsor

Shanghai Kechow Pharma, Inc.